Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada.
Frequently asked questions
What sector does Thiogenesis Therapeutics Corp. (TTI) operate in?
Thiogenesis Therapeutics Corp. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Thiogenesis Therapeutics Corp. (TTI) current stock price?
As of the latest data, Thiogenesis Therapeutics Corp. stock price is CA$0.57, with a previous close of CA$0.55. Thiogenesis Therapeutics Corp. gained CA$0.02 in the last trading session, representing a 3.64% increase.
What is Thiogenesis Therapeutics Corp. (TTI) current market capitalization?
Thiogenesis Therapeutics Corp. market cap is approximately 29.55 million.
What is Thiogenesis Therapeutics Corp. (TTI) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.14.
Does Thiogenesis Therapeutics Corp. (TTI) pay dividends?
No. Thiogenesis Therapeutics Corp. does not pay a dividend.
When is Thiogenesis Therapeutics Corp. (TTI) next earnings report?
Thiogenesis Therapeutics Corp. is expected to release its next earnings report on June 30, 2026.
What is Thiogenesis Therapeutics Corp. (TTI) beta (volatility) score?
Thiogenesis Therapeutics Corp. has a beta of 0.568, indicating lower volatility than the overall market.